Emerging therapeutic targets in oncology: Urokinase-type plasminogen activator system

Expert Opinion on Therapeutic Targets

Volumn 3, Issue 1, 1999, Pages 109-133

  Magill, Catherine ^a   Katz, Bradley A ^a   MacKman, Richard L ^a  

^a Axys Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000356819     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.3.1.109     Document Type: Article

References (160)

1. LIOTTA LA, STETLER-STEVENSON WG: Principles of molecular cell biology of cancer: Cancer metastasis. In: Cancer: Principles and Practice of Oncology. Vincent J, De-Vita T, Hellman S and Rosenberg SA (Eds.), JB Lippincott, Philadelphia, PA (1993):134-149.
2. WOODHOUSE EC, CHUAQUI RF, LIOTTA LA: General mechanisms of metastasis. Cancer (1997) 80(8 Suppl.):1529-1537.
3. DIMITROFF CJ, SHARMA A, BERNACKI RJ: Cancer metastasis: a search for therapeutic inhibition. Cancer Invest. (1998) 16(4):279-290.
4. FOLKMAN J: Tumor Angiogenesis. In: The Molecular Basis of Cancer. Mendelsohn J, Howley PM, Israel MA and Liotta LA (Eds.), W.B. Saunders Company, Philadelphia, PA (1995):206-232.
5. PRESTA M, RIFKIN DB: New aspects of blood vessel growth: tumor and tissue-derived angiogenesis factors. Haemostasis (1988) 18(1):6-17.
6. KLAGSBRUN M, D'AMORE PA: Regulators of angiogenesis. Annu. Rev. Physiol. (1991) 53:217-239.
7. AUERBACH W, AUERBACH R: Angiogenesis inhibition: a review. Pharmacol. Ther. (1994) 63(3):265-311.
8. FIDLER IJ, ELLIS LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell (1994) 79(2):185-1888.
9. SIPOS EP, TAMARGO RJ, WEINGART JD, BREM H: Inhibition of tumor angiogenesis. Ann. NY Acad. Sci. (1994) 732:263-272.
10. BATTEGAY EJ: Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. (1995) 73(7):333-346.
11. BIKFALVI A: Significance of angiogenesis in tumour progression and metastasis. Eur. J. Cancer (1995) 31A(7/8):1101-1104.
12. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86(3):353-364.
13. WEINGART JD, LATERRA JJ, BREM H: Cerebral gliomas. Growth factors and angiogenesis. Baillieres Clin. Neurol. (1996) 5(2):307-318.
14. PLUDA JM: Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol. (1997) 24(2):203-218.
15. TAUNTON J: How to starve a tumor. Chem. Biol. (1997) 4(7):493-496.
16. ZETTER BR: Angiogenesis and tumor metastasis. Ann. Rev. Med. (1998) 49:407-424.
17. O'REILLY MS, HOLMGREN L, CHEN C, FOLKMAN J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. (1996) 2(6):689-692.
18. BOEHM T, FOLKMAN J, BROWDER T, O'REILLY MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390(6658):404-407.
19. PEPPER MS, MONTESANO R: Proteolytic balance and capillary morphogenesis. Cell Differ. Dev. (1990) 32:319-328.
20. BASBAUM CB, WERB Z: Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr. Opin. Cell Biol. (1996) 8(5):731-738.
21. EDWARDS DR, MURPHY G: Cancer. Proteases-invasion and more. Nature (1998) 394(6693):527-528.
22. BIRKEDAL-HANSEN H: Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell. Biol. (1995) 7(5):728-735.
23. CHAMBERS AF, MATRISIAN LM: Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. (1997) 89(17):1260-1270.
24. DANO K, ANDREASEN PA, GRONDAHL-HANSEN J et al.: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. (1985) 44:139-266.
25. SAKSELA O: Plasminogen activation and regulation of pericellular proteolysis. Biochim. Biophys. Acta. (1985) 823:35-65.
26. BLASI F, VASSALLI J-D, DANO K: Urokinase-type plasminogen activator: Proenzyme, receptor and inhibitors. J. Cell Biol. (1987) 104:801-804.
27. SAKSELA O, RIFKIN DB: Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. (1988) 4:93-126.
28. BLASI F, VERDE P: Urokinase-dependent cell surface proteolysis and cancer. Semin. Cancer Biol. (1990) 1(2):117-126.
29. TESTA JE, QUIGLEY JP: The role of urokinase-type plasminogen activator in aggressive tumor cell behaviour. Cancer Metastasis Rev. (1990) 9:353-367.
30. VASSALLI J-D, SAPPINO A-P, BELIN D: The plasminogen activator/plasmin system. J. Clin. Invest. (1991) 88:1067-1072.
31. SCHMITT M, JANICKE F, MONIWA et al.: Tumorassociated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe-Seyler. (1992) 373:611-622.
32. DANO K, BEHRENDT N, BRUNNER Net al.: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis (1994) 8(suppl. 1):189-203.
33. FAZIOLI F, BLASI F: Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci. (1994) 15(1):25-29.
34. SCHMITT M, WILHELM O, JANICKE F et al.: Urokinasetype plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis. J. Obstet. Gynaecol. (1995) 21(2):151-165.
35. ANDREASEN PA, KJOLLER L, CHRISTENSEN L, DUFFY MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer (1997) 72:1-22.
36. RABBANI SA, XING RH: Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. (1998) 12(4):911-920.
37. STACK MS, ELLERBROEK SM, FISHMAN DA: The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma [Review]. Int. J. Oncol. (1998) 12:569-576.
38. LIJNEN HR, VAN HOEF B, COLLEN D: Activation with plasmin of two-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin. Eur. J. Biochem. (1987) 169(2):359-364.
39. FRENETTE G, TREMBLAY RR, LAZURE C, DUBE JY: Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer (1997) 71(5):897-899.
40. STACK MS, JOHNSON DA: Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J . Biol. Chem. (1994) 269(13):9416-9419.
41. PLOW EF, HERREN T, REDLITZ A, MILES LA, HOOVERPLOW JL: The cell biology of the plasminogen system. FASEB J. (1995) 9(10):939-45.
42. MIGNATTI P, RIFKIN DB: Plasminogen activators and angiogenesis. Curr. Top. Microbiol. Immunol. (1996) 213:33-50.
43. STEFFENS GJ, GUNZLER WA, OTTING F, FRANKUS E, FLOHE L: The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe Seylers Z Physiol. Chem. (1982) 363(9):1043-1058.
44. BLASI F: Surface receptors for urokinase plasminogen activator. Fibrinolysis (1988) 2:73-84.
45. HEKMAN CM, LOSKUTOFF DJ: Fibrinolytic pathways and the endothelium. Semin. Thromb. Hemost. (1987) 13(4):514-527.
46. HIGAZI AA-R, MAZAR A, WANG J et al.: Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor Type 1. Blood (1996) 87(9):3545-3549.
47. HE C, WILHELM SM, PENTLAND AP et al.: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. USA. (1989) 86(8):2632-2636.
48. LYONS RM, KESKI-OJA J, MOSES HL: Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol. (1988) 106(5):1659-1665.
49. ODEKON LE, BLASI F, RIFKIN DB: Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J. Cell Physiol. (1994) 158(3):398-407.
50. NUSRAT AR, CHAPMAN HA JR: An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest. (1991) 87(3):1091-1097.
51. GYETKO MR, TODD RF III, WILKINSON CC, SITRIN RG: The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. (1994) 93(4):1380-1387.
52. BUSSO N, MASUR SK, LAZEGA D, WAXMAN S, OSSOWSKI L: Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. (1994) 126(1):259-270.
53. RESNATI M, GUTTINGER M, VALCAMONICA S et al.: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. (1996) 15(7):1572-1582.
54. HOYER-HANSEN G, PLOUG M, BEHRENDT N, RONNE E, DANO K: Cell-surface acceleration of urokinasecatalyzed receptor cleavage. Eur. J. Biochem. (1997) 243(1-2):21-26.
55. CONESE M, NYKJAER A, PETERSEN CMet al.: alpha-2 Macroglobulin receptor/Ldl receptor-related protein( Lrp)-dependent internalization of the urokinase receptor. J. Cell Biol. (1995) 131(6 Pt 1):1609-1622.
56. CONESE M, BLASI F: Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol. Chem. Hoppe Seyler (1995) 376(3):143-155.
57. NYKJAER A, CONESE M, CHRISTENSEN EI et al.: Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBOJ. (1997) 16(10):2610-2620.
58. CHAPMAN HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. (1997) 9:714-724.
59. BLASI F: uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today. (1997) 18(9):415-417.
60. GYETKO MR, CHEN G-H, MCDONALD RA et al.: Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J. Clin. Invest. (1996) 97(8):1818-1826.
61. SHAPIRO RL, DUQUETTE JG, NUNES I et al.: Urokinasetype plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am. J. Pathol. (1997) 150(1):359-369.
62. CARMELIET P, SCHOONJANS L, KIECKENS L et al.: Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 368(6470):419-424.
63. HILDENBRAND R, DILGER I, HORLIN A, STUTTE HJ: Urokinase and macrophages in tumour angiogenesis. Br. J. Cancer (1995) 72(4):818-823.
64. HILDENBRAND R, DILGER I, HORLIN A, STUTTE HJ: Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol. Res. Pract. (1995) 191(5):403-409.
65. NAKATA S, ITO K, FUJIMORI Met al.: Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int. J. Cancer (1998) 79(2):179-186.
66. PEPPER MS, VASSALLI J-D, MONTESANO R, ORCI L: Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol. (1987) 105(6):2535-2541.
67. PEPPER MS, SAPPINO A-P, STOCKLIN R et al.: Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. (1993) 122(3):673-684.
68. KOOLWIJK P, VAN ERCK MGM, DE VREE WJA et al.: Cooperative effect of TNFa, bFGF and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. (1996) 132(6):1177-1188.
69. SCHNAPER HW, BARNATHAN ES, MAZAR A et al.: Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J. Cell Physiol. (1995) 165:107-118.
70. GUALANDRIS A, CONEJO TL, GIUNCIUGLIO D et al.: Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. Microvasc. Res. (1997) 53:254-260.
71. GROSS JL, MOSCATELLI D, RIFKIN DB: Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc. Natl. Acad. Sci. USA. (1983) 80:2623-2627.
72. PEPPER MS, BELIN D, MONTESANO R, ORCI L, VASSALLI J-D: Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogeneic properties of endothelial cells in vitro. J. Cell Biol. (1990) 111:743-755.
73. BLEI F, WILSON EL, MIGNATTI P, RIFKIN DB: Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell Physiol. (1993) 155(3):568-578.
74. PEPPER MS, VASSALLI J-D, WILKS JW et al.: Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell Biochem. (1994) 55(4):419-434.
75. TAKANO S, GATELY S, NEVILLE ME et al.: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinasetype plasminogen activator. Cancer Res. (1994) 54(10):2654-2660.
76. MANDRIOTA SJ, SEGHEZZI G, VASSALLI J-D et al.: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem. (1995) 270(17):9709-9716.
77. LEE H, STRUMAN I, CLAPP C, MARTIAL J, WEINER RI: Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology (1998) 139(9):3696-3703.
78. SHAPIRO RL, DUQUETTE JG, ROSES DF et al.: Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. (1996) 56:3597-3604.
79. SABAPATHY KT, PEPPER MS, KIEFER F et al.: Polyoma middle T-induced vascular tumor formation: The role of the plasminogen activator/plasmin system. J. Cell Biol. (1997) 137(4):953-963.
80. OSSOWSKI L, REICH E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell (1983) 35:611-619.
81. YU H, SCHULTZ RM: Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. (1990) 50(23):7623-7633.
82. OSSOWSKI L, RUSSO-PAYNE H, WILSON EL: Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res. (1991) 51:274-281.
83. KOBAYASHI H, OHI H, SUGIMURA M et al.: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. (1992) 52:3610-3614.
84. NISHIMURA Y, YASUI W, YOSHIDA K et al.: A serine protease-inhibitory benzamidine derivative inhibits the growth of human colon carcinoma cells. Jpn. J. Cancer Res. (1992) 83:723-728.
85. BILLSTROM A, HARTLEY-ASP B, LECANDER I, BATRA S, ASTEDT B: The urokinase inhibitor paminobenzamidine inhibits growth of a human prostate tumor in scid mice. Int. J. Cancer (1995) 61:542-547.
86. WILHELM O, SCHMITT M, HOHL S, SENEKOWITSCH R, GRAEFF H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Metastasis (1995) 13(4):296-302.
87. RABBANI SA, HARAKIDAS P, DAVIDSON DJ, HENKIN J, MAZAR AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer (1995) 63:840-845.
88. JANKUN J, KECK RW, SKRZYPCZAK-JANKUN E, SWIERCZ R: Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. (1997) 57(4):559-563.
89. KAWAZOE Y, SAWADA T, CHUNG Y-S, SOWA M: Role of urokinase-type plasminogen activator and inhibitory effect of protease inhibitor in invasion and metastasis of pancreatic cancer. Int. J. Oncology. (1997) 10:983-987.
90. CROWLEY CW, COHEN RL, LUCAS et al.: Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA (1993) 90:5021-5025.
91. KOBAYASHI H, GOTOH J, FUJIE M et al.: Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer (1994) 57:727-733.
92. MIN HY, DOYLE LV, VITT CR et al.: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. (1996) 56:2428-2433.
93. EVANS CP, ELFMAN F, PARANGI S et al.: Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res. (1997) 57:3594-3599.
94. KOBAYASHI H, SHINOHARA H, FUJIE M et al.: Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Ont. J. Cancer (1995) 63:455-462.
95. IGNAR DM, ANDREWS JL, WITHERSPOON SM et al.: Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin. Exp. Metastasis (1998) 16(1):9-20.
96. JANICKE F, SCHMITT M, GRAEFF H Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their Type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. (1991) 17(3):303-312.
97. GRONDAHL-HANSEN J, CHRISTENSEN IJ, ROSENQUIST C et al.: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. (1993) 53(11):2513-2521.
98. JANICKE F, SCHMITT M, PACHE L et al.: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat. (1993) 24(3):195-208.
99. HEISS MM, BABIC R, ALLGAYER H et al.: Tumorassociated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol. (1995) 13(8):2084-2093.
100. GRONDAHL-HANSEN J, HILSENBECK SG, CHRISTENSEN IJ et al.: Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res. Treat. (1997) 43(2):153-163.
101. BAJOU K, NOEL A, GERARD RD et al.: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med. (1998) 4(8):923-928.
102. RAO NK, SHI GP, CHAPMAN HA: Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J. Clin. Invest. (1995) 96(1):465-474.
103. DENG G, CURRIDEN SA, WANG S, ROSENBERG S, LOSKUTOFF DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptormediated cell adhesion and release? J. Cell Biol. (1996) 134(6):1563-1571.
104. PLANUS E, BARLOVATZ-MEIMON G, ROGERS RA et al.: Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J. Cell Sci. (1997) 110(Pt 9):1091-1098.
105. WALTZ DA, NATKIN LR, FUJITA RM, WEI Y, CHAPMAN HA: Plasmin and plasminogen activator inhibitor Type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. (1997) 100(1):58-67.
106. BOHUSLAV J, HOREJSI V, HANSMANN C et al.: Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. (1995) 181(4):1381-1390.
107. WEI Y, LUKASHEV M, SIMON DI et al.: Regulation of integrin function by the urokinase receptor. Science (1996) 273(5281):1551-1555.
108. KONAKOVA M, HUCHO F, SCHLEUNING WD: Downstream targets of urokinase-type plasminogenactivator-mediated signal transduction. Eur. J. Biochem. (1998) 253(2):421-429.
109. STEFANSSON S, LAWRENCE DA: The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 383(6599):441-443.
110. YEBRA M, PARRY GCN, STROMBLAD S et al.: Requirement of receptor-bound urokinase-type plasminogen activator for integrin avb-directed cell migration. J. Biol. Chem. (1996) 271(46):29393-29399.
111. KJOLLER L, KANSE SM, KIRKEGAARD T et al.: Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. (1997) 232(2):420-429.
112. CUBELLIS MV, WUN T-C, BLASI F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. (1990) 9(4):1079-1085.
113. NOWAK UK, LI X, TEUTEN AJ, SMITH RA, DOBSON CM: NMR studies of the dynamics of the multidomain protein urokinase-type plasminogen activator. Biochemistry (1993) 32(1):298-309.
114. STEPHENS RW, BOKMAN AM, MYOHANEN HT et al.: Heparin binding to the urokinase kringle domain. Biochemistry (1992) 31(33):7572-7579.
115. LI X, BOKMAN AM, LLINAS M, SMITH RA, DOBSON CM: Solution structure of the kringle domain from urokinase-type plasminogen activator. J. Mol. Biol. (1994) 235(5):1548-1559.
116. HANSEN AP, PETROS AM, MEADOWS RP et al.: Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry (1994) 33(16):4847-4864.
117. SPRAGGON G, PHILLIPS C, NOWAK UK et al.: The crystal structure of the catalytic domain of human urokinasetype plasminogen activator. Structure (1995) 3(7):681-691.
118. KRAUT J: Serine proteases: structure and mechanism of catalysis. Ann. Rev. Biochem. (1977) 46:331-358.
119. LESK AM, FORDHAM WD: Conservation and variability in the structures of serine proteinases of the chymotrypsin family. J. Mol. Biol. (1996) 258(3):501-537.
120. SCHECHTER I, BERGER A: On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. (1967) 27(2):157-162.
121. FREER ST, KRAUT J, ROBERTUS JD, WRIGHT HT, XUONG NH: Chymotrypsinogen: 2.5-angstrom crystal structure, comparison with alpha-chymotrypsin, and implications for zymogen activation. Biochemistry (1970) 9(9):1997-2009.
122. LAMBA D, BAUER M, HUBER R et al.: The 2.3 A crystal structure of the catalytic domain of recombinant twochain human tissue-type plasminogen activator. J. Mol. Biol. (1996) 258(1):117-135.
123. ADAMS DS, GRIFFIN LA, NACHAJKO WR, REDDY VB, WEI CM: A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. J. Biol. Chem. (1991) 266(13):8476-8482.
124. RIJKEN DC, GROENEVELD E: Substrate specificity of tissue-type and urokinase-type plasminogen activators. Biochem. Biophys. Res. Commun. (1991) 174(2):432-438.
125. LORAND L, CONDIT EV: Ester hydrolysis by urokinase. Biochemistry (1965) 4:265-270.
126. YANG H, HENKIN J: Competitive inhibitors of human urokinase. Fibrinolysis (1992) 6(Suppl. 1):31-34.
127. OKAMATO S, HIJIKATA A: Rational approaches to proteinase inhibitors. In: Drug Design. Ariens EJ (Ed.), Academic Press, (1975):143-159.
128. GERATZ JD, CHENG MCF: The inhibition of urokinase by aromatic diamidines. Thromb. Diath. Haemorrh. (1975) 33(2):230-243.
129. GERATZ JD, SHAVER SR, TIDWELL RR: Inhibitory effect of amidino-substituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinaseinduced plasminogen activation. Thromb. Res. (1981) 24(1-2):73-83.
130. STURZEBECHER J, MARKWARDT F: Synthetische inhibitoren der serinproteinasen. Pharmazie (1978) 33(H.9):599-602.
131. TIDWELL RR, GERATZ JD, DANN O et al.: Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases. J. Med. Chem. (1978) 21(7):613-623.
132. VASSALLI J-D, BELIN D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. (1987) 214(1):187-191.
133. YANG H, HENKIN J, KIM KH, GREER J: Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. J. Med. Chem. (1990) 33(11):2956-2961.
134. TOWLE MJ, LEE A, MADUAKOR EC et al.: Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor. Cancer Res. (1993) 53:2553-2559.
135. OGSTEN D: Inhibition of the plasminogen activator urokinase by alpha-tocopherol. Acta. haemat. (1982) 67:114-118.
136. MARES-GUIA M, SHAW E: The specific inactivation of trypsin by ethyl p-guanidinobenzoate. J. Biol. Chem. (1967) 242(24):5782-5788.
137. ADLER G, REINSHAGEN M, GOKE B: Effect of camostat on exocrine pancreatic function in humans. Biomed. Res. (1989) 10(Suppl. 1):1-7.
138. SENOKUCHI K, NAKAI H, NAKAYAMA Y et al.: New orally active serine protease inhibitors. J. Med. Chem. (1995) 38(14):2521-2523.
139. KETTNER C, SHAW E: The susceptibility of urokinase to affinity labeling by peptides of arginine chloromethyl ketone. Biochim. Biophys. Acta. (1979) 569(1):31-40.
140. COLEMAN P, KETTNER C, SHAW E: Inactivation of the plasminogen activator from HeLa cells by peptides of arginine chloromethyl ketone. Biochim. Biophys. Acta. (1979) 569(1):41-51.
141. LIJNEN HR, UYTTERHOEVEN M, COLLEN D: Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. Thromb. Res. (1984) 34(5):431-437.
142. REBOUD-RAVAUX M, DESVAGES G, CHAPEVILLE F: Irreversible inhibition and peptide mapping of urinary plasminogen activator urokinase. FEBS Lett. (1982) 140(1):58-62.
143. REBOUD-RAVAUX M, VILAIN AC, BOGGETTO N et al.: A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator. Biochem. Biophys. Res. Commun. (1991) 178(1):352-359.
144. WAKSELMAN M, XIE J, MAZALEYRAT JP et al.: New mechanism-based inactivators of trypsin-like proteinases. Selective inactivation of urokinase by functionalized cyclopeptides incorporating a sulfoniomethyl-substituted m-aminobenzoic acid residue. J. Med. Chem. (1993) 36(11):1539-1547.
145. MEHDI S: Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg. Chem. (1993) 21:249-259.
146. SHEA JP: 'Approaches to coagulation cascade protease inhibition using rational drug design and SMARTTM library chemistry'.Beyond Heparin-Novel anticoagulants and emerging applications. San Diego, CA. (May 27-29, 1998).
147. DEADMAN JJ, ELGENDY S, GOODWIN CA et al.: Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J. Med. Chem. (1995) 38(9):1511-1522.
148. KE SH, COOMBS GS, TACHIAS K, COREY DR, MADISON EL: Optimal subsite occupancy and design of a selective inhibitor of urokinase. J. Biol. Chem. (1997) 272(33):20456-20462.
149. NIEUWENHUIZEN W, WIJNGAARDS G, GROENEVELD E: Synthetic substrates and the discrimination between urokinase and tissue plasminogen activator activity. Thromb. Res. (1977) 11(1):87-89.
150. VASSALLI J-D, BACCINO D, BELIN D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. (1985) 100(1):86-92.
151. STOPPELLI MP, CORTI A, SOFFIENTINI A et al.: Differentiation-enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA (1985) 82(15):4939-4943.
152. APPELLA E, ROBINSON EA, ULLRICH SJ et al.: The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem. (1987) 262(10):4437-4440.
153. BEHRENDT N, RONNE E, DANO K: Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. Biol. Chem. (1993) 268(8):5985-5989.
154. PLOUG M, ELLIS V, DANO K: Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1- naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry (1994) 33(30):8991-8997.
155. SMITH EM: From libraries of mixtures to potent single compounds. Development of uPAR antagonists. SRI Conference, Philadelphia, PA. (1998).
156. KATZ BA, FINER-MOORE J, MORTEZAEI R, RICH DH, STROUD RM: Episelection: novel Ki approximately nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface. Biochemistry (1995) 34(26):8264-8280.
157. VIJAYALAKSHMI J, PADMANABHAN KP, MANN KG, TULINSKY A: The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci. (1994) 3(12):2254-2271.
158. PADMANABHAN K, PADMANABHAN KP, TULINSKY A et al.: Structure of human des(1-45) factor Xa at 2.2 A resolution. J. Mol. Biol. (1993) 232(3):947-966.
159. KATZ BA, LIU B, BARNES M, SPRINGMAN EB: Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Protein Sci. (1998) 7(4):875-885.
160. NAVIA MA, MCKEEVER BM, SPRINGER JP et al.: Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84-A resolution. Proc. Natl. Acad. Sci. USA (1989) 86(1):7-11.